Low-profile biotech led by Bristol Myers vets grabs a suite of adenosine receptor antagonists via tiny buyout
A small biotech with big immunotherapy dreams out of Westport, CT, is jumping into the adenosine pathway with both feet.
Portage Biotech — which is led by two Bristol Myers Squibb vets, CEO Ian Walters and CSO Robert Kramer — is buying out New York’s Tarus Therapeutics in a $21 million all-stock deal that gives it $3 million worth of liabilities on top of four adenosine receptor antagonists, two of which are already in Phase I/II trials.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.